Could a sleep pill ward off Alzheimer's? new trial aims to find out
NCT ID NCT07213349
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether daridorexant, a sleep medication, can help the brain clear proteins linked to Alzheimer's disease. The trial includes 240 adults without dementia, regardless of sleep issues. Participants take the drug or a placebo nightly for one year, and researchers measure changes in Alzheimer's-related proteins in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
daridorexant (a sleep medication)
What this could lead to
If successful, this could point toward a new way to prevent Alzheimer's disease by improving brain waste clearance during sleep.
What could go wrong
This is an early phase 2 trial with only 240 participants, so results may not apply broadly. The study measures biological markers, not actual prevention of dementia, and the drug may not show a meaningful effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre StoP-Alzheimer (Douglas Mental Health University Institute - Research Centre)
RECRUITINGMontreal, Quebec, H4H 1R3, Canada
Contact
Contact